Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 7, 2008, Pages 1648-1652

  Jiang, Naomi Y ^a   Woda, Bruce A ^b   Banner, Barbara F ^b   Whalen, Giles F ^b   Dresser, Karen A ^b   Lu, Di ^b,c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Department of Pathology Three Biotech ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR SP1;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASSACHUSETTS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SP1 TRANSCRIPTION FACTOR; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 53549129746     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2791     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
3. Evans DB, Abruzzese JL, Rich TA. Cancer of pancreas. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins; 2001.
4. McGrath PC, Sloan DA, Kenady DE. Surgical management of pancreatic carcinoma. Semin Oncol 1996;23:200-12.
5. Yeo TP, Hruban RH, Leach SD, et al. Pancreatic cancer. Curr Probl Cancer 2002;26:176-275.
6. Kleeff J, Michalski C, Friess H, Buchler MW. Pancreatic cancer: from bench to 5-year survival. Pancreas 2006;33:111-8.
7. Farnell MB, Pearson RK, Sarr MG, et al. Aprospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618-28.
8. Marsh RW, George T. Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma. Curr Gastroenterol Rep 2006;8:111-20.
9. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, chacterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 2006;5:787-96.
10. Philipsen S, Suske G, A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucleic Acids Res 1999;27:2991-3000.
11. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and Krüppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001;188:143-60.
12. Lack AR, Azizkhan JC. Transcriptional regulation of growth related genes by E2F and Sp1. The Pezoller Foundation Journal 1996;3:4-16.
13. Safe S, Adbelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer 2005;41:2438-48.
14. Lou Z, O'Reilly S, Liang H, Maher VM, Sleight SD, McCormick JJ. Down-regulation of overexpressed Sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 2005;65:1007-17.
15. Jiang Y, Wang L, Gong W, et al. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis 2004;21:755-64.
16. Blasco F, Penuelas S, Cascallo M, et al. Expression profiles of a human cancer cell line upon induction of apoptosis: serch for modulators in cancer therapy. Oncology 2004;67:277-90.
17. Jiang Z, Chu PG, Woda BA, et al. Analysis if RNA-binding protein IMP3 to predict metastasis and prognosis of renal cell carcinoma: a retrospective study. Lancet Oncol 2006;7:556-64.
18. Chun RF, Semmes OJ, Neuveut C, Jeang KT. Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat. J Virol 1998;72:2615-29.
19. Haltiwanger RS, Grove K, Philipsberg GA. Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-β-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino-N-phenylcarbamate. J Biol Chem 1998;273:3611-7.
20. Ishibashi H, Nakagawa K, Onimaru M, et al. Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor β1, and tissue factor and also cell growth and invasion activities. Cancer Res 2000;60:6531-6.
21. Lee RJ, Albanese C, Fu M, et al. Cyclin D1 is required for trasformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 2000;20:672-83.
22. Abdelrahim M, Baker CH, Abbruzzese JL, et al. Regulation of vascular endothelial growth factor receptor-1 expression by specific 1, 3, and 4 in pancreatic cancer cells. Cancer Res 2007;67:3286-94.
23. Jungert K, Buck A, von Wichert G, et al. Sp1 is required for transforming growth factor-β induced mesenchymal transition and migration in pancreatic cancer cells. Cancer Res 2007;67:1563-70.
24. Takami Y, Russell MB, Gao C, Mi Z, Guo H, Mantyh CR, Kuo PC. Sp1 regulates osteopontin in SW480 human colon adenocarcinoma cells. Surgery 2007;142:163-9.
25. Zhang W, Geiman DE, Shields JM, et al. The gut-enriched Krupple-like factor mediates the transactivating effect of p53 on the p21WAF1/Clip1 promoter. J Biol Chem 2001;275:18391-8.
26. Cowgill SM, Muscarella P. The genetics of pancreatic cancer. Am J Surg 2003;186:279-86.
27. Kaluz S, Kaluzova M, Stanbridge EJ. Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. Cancer Res 2003;63:917-22.
28. Kwak HJ, Park MJ, Cho H, et al. Transforming growth factor-β1 induces tissue inhibition of metalloproteinase-1 expression via activation of extracellular signal-regulated kinase and Sp1 in human fibrosarcoma cells. Mol Cancer Res 2006;4:209-20.